Expression of interstitial collagenase (MMP-1) has been detected in stromal ®broblasts of various malignant tumors. Here, we have studied the eect of three structurally dierent ETS transcription factors (ETS-1, ERGB/Fli-1, and PU.1) on MMP-1 promoter activity in NIH3T3 ®broblasts. ETS-1 increased the activity of 3.8 kb MMP-1 promoter construct up to tenfold, while ERGB/Fli-1 or PU.1 alone had no marked eect on basal promoter activity. ETS-1 also markedly potentiated enhancement of MMP-1 promoter by both c-Jun and JunB, whereas ERGB/Fli-1 augmented only the eect of c-Jun. Interestingly, PU.1 abolished induction of MMP-1 promoter by both c-Jun and JunB. Stimulation of MMP-1 promoter by 12-O-tetradecanoyl phorbol-13-acetate and okadaic acid was dierentially augmented by ETS-1 and ERGB/Fli-1, and abrogated by PU.1. Cotransfection studies with MMP-1 promoter 5'-deletion constructs revealed that AP-1 site was necessary for PU.1-elicited suppression. As compared to control cell lines, PU.1-positive stable cells exhibited clearly weaker binding of c-Jun and JunD containing AP-1 complexes to MMP-1 promoter AP-1 element, as well as marked reduction in basal level and induction of c-jun mRNA by 12-O-tetradecanoyl phorbol-13-acetate and okadaic acid, suggesting a novel mechanism for PU.1-mediated inhibition of AP-1 dependent gene expression. These results show that three structurally distinct ETS transcription factors dierently modulate AP-1 dependent upregulation of MMP-1 gene expression.
Introduction
Matrix metalloproteinases (MMPs) are a family of 14 structurally related zinc-dependent neutral endopeptidases collectively capable of degrading essentially all components of extracellular matrix. MMPs participate in connective tissue remodeling in physiologic conditions including developmental tissue morphogenesis, angiogenesis and tissue repair. In addition, MMPs play an important role in excessive tissue breakdown e.g. in rheumatoid arthritis, autoimmune blistering skin disorders, and in tumor cell invasion and metastasizing (see Birkedal-Hansen et al., 1993) . Interstitial collagenase (MMP-1), neutrophil collagenase (MMP-8) and collagenase-3 (MMP-13) are the only secreted neutral proteinases capable of degrading ®brillar collagens of types I, II, and III (Birkedal-Hansen, 1995) . Since ®brillar collagens are the most abundant structural components of human connective tissues, the ability to degrade them is crucial for invasion and metastasizing of neoplastic cells. Expression of MMP-1 has been observed in lung carcinomas (Urbanski et al., 1992; Wernert et al., 1994) , squamous cell carcinomas of the head and neck (Polette et al., 1991; Muller et al., 1991; Gray et al., 1992) , and in colorectal tumors, in which expression of MMP-1 correlates with poor prognosis (Hewitt et al., 1991; Murray et al., 1996) . In these tumors, stromal cells appear to be responsible for MMP-1 production, indicating importance of crosstalk between tumor and stromal cells in tumor cell invasion (for review see Stetler-Stevenson et al., 1993; Wernert et al., 1994; Bolon et al., 1995) . Recently, a tumor cell-derived factor called extracellular matrix metalloproteinase inducer (EMMPRIN) was shown to induce MMP-1 expression by ®broblasts providing a putative mechanism for tumor cell-elicited activation of matrix degradation by stromal ®broblasts (Biswas et al., 1995) .
The expression of MMP-1 is induced at transcriptional level by a variety of cytokines and growth factors, such as interleukin-1 (IL-1), tumor necrosis factor-a (TNF-a), and epidermal growth factor (EGF), as well as by tumor promoters (Mauviel, 1993) . These extracellular stimuli result in activation of nuclear AP-1 transcription factor complex, which then binds to its cognate cis-element at position 772 to 765 in the MMP-1 promoter and activates transcription (see Matrisian, 1994) . AP-1 dimers are composed of the members of Jun and Fos gene families (Angel and Karin, 1991) . DNA binding anity and transactivation capacity of AP-1 dimers is dependent on phosphorylation of the constituent factors, as demonstrated by increased trans-activation capacity of c-Jun containing AP-1 dimers as a result of phosphorylation of two serine residues in the trans-activation domain of c-Jun by Jun N-terminal kinases (JNKs) (see Hunter and Karin, 1992; Karin, 1995) .
Recently, another functional cis-element, PEA3 site, was identi®ed in the proximity of AP-1 motif in the human MMP-1 promoter. This element binds members of the ETS-family of transcription factors and cooperates with the AP-1 motif to achieve maximal 12-Otetradecanoyl 13-phorbol acetate (TPA)-elicited activation of a promoter construct containing a tetramer of oligonucleotides, encompassing the ETS and AP-1 elements of MMP-1 promoter, in front of a hetero-logous promoter (Gutman and Wasylyk, 1990 ). An ETS-related factor E1A-F has also been shown to activate promoters of MMP-1, stromelysin-1 (MMP-3), and 92 kDa gelatinase (MMP-9) genes in MG-63 cells (Higashino et al., 1995) . In addition, overexpression of both ETS-1 and ETS-2 eciently stimulates the activity of MMP-3 promoter (Wasylyk et al., 1991; Buttice and Kurkinen, 1993) .
The members of ETS family are characterized by homologous C-terminal DNA binding domain, which recognizes purine-rich DNA core sequence A/CGGAA, found in the 5'-¯anking regulatory regions of numerous genes (see Seth et al., 1992) . ETS proteins can be classi®ed according to their homology to ETS-1. Class I members (e.g. v-ETS) display signi®cant structural homology to ETS-1, whereas class II members (e.g. ERGB/Fli-1) show homology to ETS-1 only in their trans-activation and DNA-binding domains . In contrast, class III members (e.g. PU.1) show homology to ETS-1 only in the C-terminal DNAbinding domain (Figure 1 ; Moreau-Gachelin, 1994) . The members of ETS gene family are preferentially expressed in lymphoid tissue, e.g. thymus and spleen. ETS-1 is also expressed in stromal ®broblasts adjacent to invading tumor cells and in endothelial cells during tumor vascularization (Wernert et al., 1992 (Wernert et al., , 1994 Bolon et al., 1995) and its expression in cultured ®broblasts is induced by TPA, TNF-a and basic ®broblast growth factor (Wernert et al., 1994) .
In this study, we have examined the eect of three structurally dierent members from distinct classes of ETS gene family, i.e. ETS-1, ERGB/Fli-1, and PU.1, on the activity of full length (3.8 kb) human MMP-1 promoter construct. We show that these ETS-factors regulate MMP-1 gene expression dierently and we propose a novel mechanism for suppression of AP-1 dependent MMP-1 gene expression by PU.1. Further characterization of domains involved in ETS-mediated regulation of MMP-1 gene expression may oer new possibilities for modulating collagenolytic capacity of neoplastic cells by means of targeted gene transfer.
Results

Structurally distinct ETS-members dierently modulate AP-1 dependent activation of MMP-1 promoter
We have recently shown that stimulation of 3.8 kb human MMP-1 promoter construct by tumor promoter okadaic acid (OA) in HT-1080 ®brosarcoma cells is mediated by JunB (Westermarck et al., 1994) . In this context, we ®rst examined the regulation of MMP-1 promoter by c-Jun and JunB in ®broblastic cells by transiently co-transfecting NIH3T3 ®broblasts with expression vectors for c-Jun or JunB in combination with 3.8 kb human MMP-1 promoter/chloramphenicol acetyltransferase (CAT) reporter gene construct pCLCAT3. In these experiments both c-Jun and JunB enhanced (six-and fourfold, respectively) the activity of MMP-1 promoter, as compared to control cultures cotransfected with the empty expression vector, indicating that in addition to c-Jun, JunB is an activator of MMP-1 expression in ®broblastic cells (Figure 2) .
It was previously shown that AP-1 and ETS transcription factors synergistically upregulate the activity of a construct, in which a tetramer of MMP-1 promoter segment encompassing the ETS and AP-1 motifs is linked to a heterologous promoter driving a reporter gene (Gutman and Wasylyk, 1990) . To elucidate the eects of structurally dierent ETSfactors on the activity of a full length human MMP-1 promoter we transiently co-transfected NIH3T3 cells with pCLCAT3 construct together with expression vectors for members of three distinct ETS-classes, namely ETS-1, ERGB/Fli-1 and PU.1 (Figure 1) , alone or together with c-Jun or JunB expression vectors. As shown in Figure 2 , overexpression of ETS-1 alone potently (tenfold) stimulated MMP-1 promoter activity, whereas ERGB/Fli-1 or PU.1 alone did not markedly alter MMP-1 promoter activity. Furthermore, ETS-1 clearly potentiated the enhancement of MMP-1 promoter activity by both c-Jun and JunB, while ERGB/Fli-1 augmented (1.5-fold) only the eect of c-Jun (Figure 2) . Interestingly, overexpression of PU.1 potently (by 60%) counteracted activation of MMP-1 promoter by both c-Jun and JunB (Figure 2 ).
To further study the modulation of AP-1 dependent induction of MMP-1 gene expression by ETS-1, ERGB/Fli-1 and PU.1, NIH3T3 cells were transiently transfected with pCLCAT3 together with these ETS Figure 1 Homologous structural domains between ETS-1, ERGB/Fli-1 and PU.1 proteins are shown Figure 2 Regulation of MMP-1 promoter activity by AP-1 and ETS transcription factors. Con¯uent NIH3T3 cell cultures were transiently co-transfected with 3.8 kb human collagenase (MMP-1) promoter/CAT construct pCLCAT3 (4 mg) together with empty expression vectors pRSV and pSG5, or with expression plasmids for c-Jun or JunB alone, or in combination with ETS-1, ERGB/Fli-1, or PU.1 expression constructs (2 mg each), as indicated. After the glycerol shock the cultures were maintained for 36 h in DMEM containing 1% FCS. Cells were then harvested and CAT activity was measured. Transfection eciency was monitored by co-transfecting the cells with 4 mg of RSV/b-galactosidase construct. The values represent mean of at least two independent experiments each performed in duplicate expression vectors, and subsequently treated for 36 h with tumor promoters TPA and OA, known to induce AP-1 activity (Lamph et al., 1988; SchoÈ nthal et al., 1991) . In accordance with our previous observations on HT-1080 cells (Westermarck et al., 1994) , both TPA and OA enhanced 3.8 kb MMP-1 promoter activity (three-and ®vefold, respectively) in NIH3T3 cells cotransfected with empty expression vector (Figure 3 ). In these experiments, overexpression of ETS-1 potentiated stimulation of pCLCAT3 activity by both TPA and OA, whereas ERGB/Fli-1 augmented (twofold) only the upregulatory eect of TPA (Figure 3 ). In contrast, PU.1 potently abrogated stimulation of MMP-1 promoter activity by both tumor promoters ( Figure  3 ). Taken together, data from these experiments show that ETS-1 and ERGB/Fli-1 dierentially modulate basal activity and AP-1-mediated upregulation of MMP-1 promoter, and that PU.1 potently blocks AP-1-mediated induction of MMP-1 promoter activity in NIH3T3 ®broblasts.
The role of ETS and AP-1 elements in PU.1-elicited downregulation of MMP-1 promoter activity
The results shown above provide evidence that expression of ETS proteins lacking the typical trans-activation domain, such as PU.1 counteract the AP-1 mediated activation of MMP-1 promoter. In this context, we wanted to identify the cis-elements in the MMP-1 promoter involved in this PU.1-mediated suppression. For this, we co-transfected NIH3T3 cells with MMP-1 promoter/CAT 5'-deletion constructs together with empty expression vector or with PU.1 expression vector and simultaneously treated these cells with TPA and OA. As shown in Figure 4 , the basal activity of the construct pCL-95CAT, which contains both ETS and AP-1 ciselements, was slightly higher as compared to pCL-72CAT, which contains only the AP-1 element. Mutation of the AP-1 element in pCL-95mAP-1CAT decreased the promoter activity by 90%, indicating that AP-1 is required for sustaining basal activity of MMP-1 promoter in these cells. However, the basal promoter activity of the pCL-55CAT, lacking both ETS and AP-1 elements was somewhat higher than the activity of pCL95mAP-1CAT (Figure 4 ), suggesting that in certain conditions ETS element may suppress the activity of a minimal promoter construct. This ®nding agrees with previous observation showing that mutation of the ETS element of a promoter construct containing a tetramer of MMP-1 promoter ETS and AP-1 elements potentiates the response of this promoter to c-Jun and c-Fos (Gutman and Wasylyk, 1990) .
Interestingly, TPA upregulated (twofold) only the activity of the construct pCL-95CAT, whereas OA enhanced the activity of all constructs, including pCL95mAP-1CAT lacking the AP-1 element and pCL-55CAT, which lacks both ETS and AP-1 elements ( Figure 4 ). This may be explained by the presence of an NF-kB-like motif at position 720 to 710 in human MMP-1 promoter (Pierce et al., 1996) , and by the fact that OA activates NF-kB (Sun et al., 1995) . Interestingly, forced expression of PU.1 in NIH3T3 cells decreased basal activity of both pCL-72CAT and pCL-95CAT but not that of pCL-95mAP-1CAT or pCL-55CAT lacking the AP-1 element (Figure 4 ), indicating that AP-1 cis-element is required for suppression of basal activity of these minimal MMP-1 promoter constructs. In addition, PU.1 markedly (by over 50%) abrogated stimulation of pCL-95CAT by TPA, and activation of pCL-95CAT and pCL-72CAT constructs by OA, indicating that PU.1 interferes with induction of MMP-1 promoter via AP-1 trans-acting factors.
Reduction in TPA and OA-elicited induction of MMP-1 promoter activity in PU.1-positive NIH3T3 cells
To further elucidate the mechanism of PU.1-elicited inhibition of MMP-1 promoter activity, we constructed a stable PU.1 expression vector pAWneoPU.1 contain- Figure 3 Modulation of TPA and OA-elicited enhancement of MMP-1 promoter activity by ETS transcription factors. Conuent NIH3T3 cell cultures were transiently transfected with 3.8 kb human collagenase (MMP-1) promoter/CAT construct pCLCAT3 (4 mg) together with the empty expression vector, or with expression plasmids for ETS-1, ERGB/Fli-1, or PU.1 (2 mg each), as indicated. After the glycerol shock the cultures were maintained for 3 h in DMEM containing 1% CS. Thereafter, OA (80 ng/ml) or TPA (60 ng/ml) were added to the culture media and incubation was continued for 36 h. Cells were then harvested and CAT activity was measured. Transfection eciency was monitored by co-transfecting the cells with 4 mg of RSV/bgalactosidase construct. The values represent mean of at least two independent experiments each performed in duplicate Figure 4 Forced expression of PU.1 in NIH3T3 cells inhibits AP-1 dependent MMP-1 promoter activity. NIH3T3 cell cultures were transiently co-transfected with pCL-72CAT, pCL-95CAT, pCL-95mAP-1CAT or pCL-55CAT, in combination with empty expression vector or PU.1 expression vector (4 mg each). After the glycerol shock the cultures were maintained for 3 h in DMEM containing 1% CS. Thereafter, OA (80 ng/ml) or TPA (60 ng/ml) were added to the culture media and incubation was continued for 36 h. Cells were then harvested and CAT activity was measured. Transfection eciency was monitored by co-transfecting the cells with 4 mg of RSV/b-galactosidase construct. The values represent mean of at least four independent experiments ing the coding region of PU.1 cDNA driven by SV40 promoter. NIH3T3 cells were transfected with pAWneoPU.1, stable neomycin resistant cell clones were pooled to overcome the eect of random integration of plasmid DNA in single clones, and re-seeded to establish ®ve parallel cell lines named pPU.1neo I-V. After the glycerol shock the cultures were maintained for 3 h in DMEM containing 1% CS, then TPA (60 ng/ml) or OA (80 ng/ml) were added to the culture media and incubation was continued for 36 h. Cells were harvested and CAT activity was measured. Transfection eciency was monitored by co-transfecting the cells with 4 mg of RSV/b-galactosidase construct. The values represent mean of three independent experiments each performed in duplicate
The level of expression of PU.1 transgene in these cell lines and in ®ve control cell lines, transfected with the empty expression vector pAWneo2, was examined by Northern blot hybridization. As shown in Figure 5a , all cell lines transfected with pAWneoPU.1 clearly expressed similar levels of PU.1 mRNA, while all control cell lines, as well as wild type NIH3T3 cells were negative for PU.1 mRNA. This is in accordance with previous observations showing PU.1 gene expression only in myeloid and B cells, due to cell type-speci®c promoter of PU.1 gene (Chen et al., 1995) . The expression of PU.1 protein in these stable cell lines was also determined by Western blot analysis using PU.1 speci®c antibody. In PU.1 transfected cells two bands of approximately 43 and 45 kDa were detected, the sizes of which are in accordance with previous observations (Hallier et al., 1996) and vector transfected cells were entirely negative for PU.1 protein (Figure 5b ). To further con®rm expression of functional PU.1 protein in these cells we performed gel mobility shift assays, in which nuclear proteins from PU.1-positive cells exhibited strong binding to labeled double-stranded oligomer containing consensus PU.1 binding site ( Figure  5c ). In addition, a clear supershift was noted after addition of PU.1 monospeci®c antibody to binding reactions. PU.1 binding was competed by 30-fold molar excess of unlabeled double stranded oligomer, containing a consensus ETS binding site (dsBETS), whereas unlabeled oligomer corresponding to ETS element from human MMP-1 promoter (dsETS) was unable to compete with PU.1 binding (Figure 5c ). Similar results were obtained in three independent gel shift assays with nuclear protein from two distinct PU.1-positive cell lines. Nuclear proteins from control cells (pAWneo) showed no speci®c binding to PU.1 probe. These results indicate that PU.1 transfected cell lines express functional PU.1 protein, which speci®cally binds to consensus PU.1 motif. The results of the competition studies provide evidence that the downregulatory eect of PU.1 on MMP-1 gene expression may not result from direct binding of PU.1 protein to the ETS element in MMP-1 promoter.
To study whether PU.1 expression in these cells leads to diminished MMP-1 promoter activity, we transiently transfected control and PU.1 positive cell lines with construct pCLCAT3. As seen in Figure 5d , the basal level of MMP-1 promoter activity was similar in both control and PU.1 positive cells. Treatment of control cells with TPA and OA resulted in marked induction of MMP-1 promoter activity (9.8 and 10.4-fold, respectively) (Figure 5d ). However, in PU.1-positive cells the induction was approximately 50% lower (Figure 5d (Figure 6 ). In contrast, no JunB binding to AP-1 element was detected in unstimulated control or PU.1 positive cells. No marked dierences were detected in binding of nuclear extracts to the oligomers containing both ETS and AP-1 elements, or only the AP-1 site (data not shown), suggesting that direct PU.1 binding to the ETS-element of MMP-1 promoter is not responsible for regulation of MMP-1 expression under these conditions.
Forced expression of PU.1 in NIH3T3 cells results in diminished basal expression and induction of c-jun mRNA
The results of gel shift assays shown above indicate that forced expression of PU.1 in NIH3T3 cells leads (Chiu et al., 1989; SchuÈ tte et al., 1989) . In turn, simultaneous expression of c-Jun and JunB inhibits activity of AP-1 responsive promoters due to formation of inactive c-Jun/JunB dimers (Deng and Karin, 1994) . However, in the presence of c-Fos, the 72 bp MMP-1 promoter construct is similarly upregulated by both c-Jun and JunB in F9 cells (Bergelson and Daniel, 1994) . In the present study, overexpression of JunB enhanced MMP-1 promoter activity in NIH3T3 cells nearly as potently as c-Jun, supporting our previous observations with HT-1080 cells (Westermarck et al., 1994) . It seems that c-Jun can upregulate MMP-1 promoter by forming c-Jun homodimers, whereas trans-activation by JunB requires dimerization with c-Fos and possibly also the presence of additional regulatory cis-elements in the 5'-¯anking region of human MMP-1 gene. The role of JunB in neoplastic cells is supported by a recent study by Neyns et al. (1996) showing that high JunB expression by epithelial ovarian cancer cells both in vitro and in vivo relates to a more malignant phenotype of these tumors. Previous studies have demonstrated requirement of the ETS binding site for maximal activation of a promoter construct containing a tetramer of ETS and AP-1 elements of MMP-1 promoter in front of a heterologous promoter by TPA (Gutman and Wasylyk, 1990) . Furthermore, have shown that overexpression of ETS-1 activates the minimal (72 bp) MMP-1 promoter. Interestingly, this construct contains only the AP-1 site, suggesting that the ETS element is not required for ETS-1 mediated upregulation of MMP-1 promoter. The results of the present study indicate that structural dierences in ETS proteins result in dierential ability to trans-activate full length (3.8 kb) human MMP-1 promoter. Overexpression of ETS-1 alone stimulated MMP-1 promoter more eciently than either c-Jun or JunB alone. Simultaneous expression of ETS-1 with c-Jun or JunB also further enhanced MMP-1 promoter activity, JunB/ ETS-1 combination being even more potent than cJun/ETS-1. In this context, it should be noted that ETS-1, ERGB/Fli-1, and PU.1 were recently shown to form complexes with c-Jun and JunB (Bassuk and Leiden, 1995) . It is possible, that in addition to direct enhancement, the potent upregulatory eect of ETS-1 on MMP-1 promoter activity may also be mediated indirectly by activation of JunB expression by ETS-1 (Coer et al., 1994) . The role of ETS-1 in the activation of MMP-1 expression in neoplastic tumors is supported by in situ hybridization studies showing co-localization of ETS-1 and MMP-1 transcripts in stromal ®broblasts in colon and lung cancers (Wernert et al., 1994; Bolon et al., 1995) .
Expression of ERGB/Fli-1 has been previously noted in lymphoid cells and we have detected ERGB/Fli-1 mRNA in human skin ®broblasts and HT-1080 ®brosarcoma cells (Westermarck et al., unpublished observations). The role of ERGB/Fli-1 or other class II ETS factors in the regulation of MMP-1 gene transcription has not been studied previously. However, it has been shown that ERGB/Fli-1 can function as transcriptional activator . In this study, overexpression of ERGB/Fli-1 alone had no marked eect on basal activity of MMP-1 promoter, while ERGB/Fli-1 augmented the upregulatory eect of c-Jun and TPA on MMP-1 promoter. Although ERGB/Fli-1 displays signi®cant homology to ETS-1 in DNA binding and trans-activation domains, our results show that unlike ETS-1, ERGB/Fli-1 alone is not capable of activating AP-1 dependent genes, but requires the presence of transcriptional activators (e.g. c-Jun), indicating differences in functional domains of ERGB/Fli.1 and ETS.1. This notion is supported by discovery of a chimeric protein EWS/Fli-1 from Ewing's sarcoma. In EWS/Fli-1, replacement of ERGB/Fli-1 trans-activation domain by a portion of EWS protein results in a chimeric transcription factor with a more potent trans-activation capacity than ERGB/Fli-1, and the ability to transform NIH3T3 cells, in contrast to wild type ERGB/Fli-1 (May et al., 1993) .
The most divergent member of ETS family is PU.1, which has marked homology to ETS-1 only in its DNA binding domain. It has been shown that PU.1 regulates several myeloid cell-speci®c promoters (Moreau-Gachelin, 1994) . In the present study, expression of PU.1 in NIH3T3 cells potently abrogated induction of 3.8 kb MMP-1 promoter activity by c-Jun and JunB, as well as by TPA and OA. Furthermore, studies with 5'-deletion constructs indicate that suppression of basal MMP-1 promoter activity by PU.1 requires presence of the AP-1 element but not the ETS binding site. Gel shift assays also show that PU.1 protein does not bind to MMP-1 promoter ETS element. This is in accordance with previous reports showing that DNA binding speci®city of PU.1 is distinct from ETS-1, and that it is determined by sequences¯anking the consensus binding site . Interestingly, we noted that expression of PU.1 protein eciently diminished binding of c-Jun and JunD containing AP-1 complexes to the AP-1 element of MMP-1 promoter. Furthermore, in stable cell lines expressing PU.1 protein the basal expression, as well as induction of c-jun mRNA by TPA and OA was diminished. In contrast, there were no marked dierences in junB or junD mRNA levels between control and PU.1 positive cells either at basal level, or after treatment with TPA or OA. Overexpression of JunD in NIH3T3 cells did not alter the activity of pCLCAT3 (data not shown), indicating that dimin-ished binding of JunD to the MMP-1 promoter AP-1 element is not involved in PU.1-elicited suppression of MMP-1 promoter activity, but may re¯ect formation of PU.1/JunD complex (Bassuk and Leiden, 1995) with reduced binding anity to MMP-1 promoter AP-1 element (Figure 8) . Interestingly, overexpression of mutant forms of ETS proteins lacking the N-terminal trans-activation domain represses transformation by Ras, but not the activity of AP-1 dependent promoter in NIH3T3 cells (Wasylyk et al., 1994; Galang et al., 1996) . This indicates that although PU.1 protein structurally resembles trans-activation-de®cient ETS proteins, the mechanism of PU.1-elicited suppression of AP-1 dependent MMP-1 promoter activity is dierent from that resulting in inhibition of Rastransformation by mutant ETS proteins.
In conclusion, the results of this study show that structural dierences between ETS transcription factors result in dierential ability to regulate MMP-1 gene expression. Furthermore, we provide evidence that in addition to direct binding of ETS transcription factors to MMP-1 promoter region, these trans-acting factors may regulate MMP-1 gene expression indirectly by modulating the expression of AP-1 transcription factors. Especially, the expression of PU.1 protein in ®broblasts potently blocks AP-1-mediated induction of MMP-1 gene expression by a mechanism, which appears to involve suppression of c-jun expression and diminished binding of c-Jun containing AP-1 dimers to MMP-1 promoter (Figure 8 ). Further characterization of the domains involved in ETSmediated regulation of MMP-1 gene expression may oer new possibilities for modulation of collagenolytic capacity of cells in pathological situations, including rheumatoid arthritis and tumor cell invasion, by means of targeted gene transfer.
Materials and methods
Cell transfections
NIH3T3 cells (ATCC, Rockville, MD) were maintained in Dulbecco's modi®ed Eagle's medium (DMEM) supplemented with 10% calf serum (CS), 2 mM glutamine, 100 IU/ml penicillin-G and 100 mg/ml streptomycin. In transient transfections, con¯uent NIH3T3 cell cultures were transfected with 2 or 4 mg of the following human MMP-1 promoter/CAT constructs: pCLCAT3, containing 3.8 kb of human MMP-1 gene 5'-¯anking region linked to CAT reporter gene (kindly provided by Dr Steven Frisch, Washington University, St Louis, MO); 5'-deletion constructs pCL-95CAT, pCL-95mAP-1CAT, pCL-72CAT and pCL-55CAT (Pierce et al., 1996) (kindly provided by Dr William C Parks, Washington University, St Louis, MO). Cells were transfected with calcium phosphate/DNA coprecipitation (Graham and van der Erb, 1973) , followed by a 2 min glycerol shock. In certain experiments okadaic acid (80 ng/ml; LC Laboratories, Woburn, MA) or TPA (60 ng/ ml; Sigma Chemical Co, St Louis,MO) was added to the cultures 3 h after the glycerol shock and the incubations were continued for 36 h.
As an index of promoter activity, CAT activity was measured from aliquots (100 ml) of cell extracts in reactions containing 0.25 M Tris-HCl buer (pH 8.0), 25 mg n-butyrylcoenzyme A (Sigma), and 0.0625 mCi of [ 14 C] chloramphenicol (Amersham, UK), in a total volume of 125 ml. The butyrylated chloramphenicol products were extracted with 300 ml of xylene after overnight incubation at 378C. The CAT activity was quantitated by scintillation counting after two back-extractions of the xylene phase with 100 ml of 0.25 M Tris-HCl. The transfection eciency was monitored by cotransfecting cells with 4 mg of RSV/b-galactosidase construct and correcting the CAT-activities for b-galactosidase activity.
In co-transfection experiments the cells were transiently transfected with the MMP-1 promoter/CAT construct pCLCAT3 (2 mg) together with 2 mg of pRSVjun, pRSVjunB (Chiu et al., 1989) , or pSVjunD (Nicolaides et al., 1992) expression constructs, either alone or in combination with 2 mg of pSGETS-1, pSGERGB/Fli-1 (Seth et al., 1994) or pSGPU.1 expression constructs to achieve overexpression of dierent Jun and ETS family members. The pSGPU.1 expression construct was generated by cloning a 859 bp PvuII-NaeI fragment of murine PU.1 cDNA (Klemsz et al., 1990) containing the coding region to the expression vector pSG5 (Stratagene, La Jolla, CA). The PU.1 protein expressed in vitro binds maximally to HER2/neu ETS binding site in gel shift assays (Seth et al., unpublished observations) . Control cultures were co-transfected in parallel with the empty expression vectors to eliminate the possibility that the effects noted would be due to competition for transcription factors by RSV or SV promoters.
For generating PU.1-positive cell lines we constructed a PU.1 expression vector pAWneoPU.1 by inserting the 859 bp PvuII-NaeI fragment of murine PU.1 cDNA from pSGPU.1, described above, into the expression vector pAWneo2 (kindly provided by Dr Arthur Weiss) (Ohashi et al., 1985) , which carries neomycin resistance gene. In stable transfections, con¯uent NIH3T3 cell cultures were transfected, as described above, either with PU.1 expression vector, or with the empty expression vector (20 mg each) and incubated overnight in fresh medium. Geneticin (G-418, Sigma) was then added in concentration 500 mg/ml and stable cell lines were selected by changing the culture medium twice a week until all cells in mock-transfected plates had died. G-418 resistant cell clones were then trypsinized, reseeded and cultured with 250 mg/ml of G-418 to ®ve parallel cell lines which were frozen immediately after reaching con¯uency.
RNA analysis
Total cellular RNA was isolated from cell cultures using guanidine thiocyanate/cesium chloride method (Chirgwin et al., 1979) . Aliquots of total RNA (20 mg) were fractionated on 0.8% agarose gels containing 2.2 M formaldehyde, transferred to Zeta probe ®lter (BioRad, Richmond, CA) by vacuum transfer (VacuGene XL, LKB, Bromma, Sweden) and immobilized by heating at 808C for 30 min. The ®lters were prehybridized for 2 h and subsequently hybridized for 20 h, as described previously (Thomas, 1980) with cDNAs labeled by [a- 32 P]dCTP using a random priming kit (Amersham, UK). The ®lters were then washed, the ®nal stringency being 0.16SSC/0.1% SDS at 608C. The cDNA-mRNA hybrids were visualized by autoradiography, and the levels of mRNAs were quantitated by scanning densitometry using MCID software (Imaging Research Inc, St Catharines, Ontario, Canada). The following cDNAs were used for hybridizations: for c-jun, a human 0.4 kb cDNA (Angel et al., 1988) ; for junB, a 1.2 kb murine cDNA (Chiu et al., 1989) ; for junD, a 1.6 kb mouse cDNA (from ATCC); for PU.1, a 0.8 kb mouse cDNA (see above); for glyceraldehyde-3-phosphate-dehydrogenase (GAPDH), a 1.3 kb rat cDNA (Fort et al., 1985) .
Gel mobility shift assays
Nuclear proteins were extracted as described previously (Andrews and Faller, 1991) . Nuclear protein-DNA binding reactions were performed using double-stranded oligomers containing (1) the PU.1 binding site (underlined) 5'-CCTCTGAAAGAGGAACTTGGT-3' ; (2) AP-1 binding site (underlined) of human collagenase (MMP-1) promoter (5'-CTAGTGATGAGT-CAGCCGGATC-3') (Angel et al., 1987) ; (3) both ETS and AP-1 binding sites (underlined, respectively) of human MMP-1 promoter (5'-GATCGAGAGGATGTTATAAAG-CATGAGTCAG-3' (Gutman and Wasylyk, 1990) . In binding reactions, 10 mg of nuclear protein extracts were incubated together with 5'-end labeled oligomers (40 000 c.p.m. per reaction) in a total volume of 25 ml for 30 min in room temperature as described previously (KaÈ haÈ ri et al., 1992) . In some reactions, speci®c antibodies raised against N-terminus of c-Jun protein, N-terminus of JunB protein, N-terminus of JunD protein and C-terminus of PU.1 protein (Santa Cruz Biotechnology, Santa Cruz, CA) were added 30 min prior to addition of the probe. In certain reactions, a 30 min or 100-fold molar excess of cold double-stranded oligomer containing (1) the consensus AP-1 binding site (underlined) (5'-CGCTTGATGAGT-CAGCCGGAA-3') (Promega, Madison, WI); (2) the consensus ETS binding site (underlined) (5'-GAGCA-CAGTCGAGGAAGTGACTAACTG) (dsBETS; Wasylyk et al., 1994) ; or (3) the ETS binding element from MMP-1 promoter (underlined) (5'-GATCGAGAGGATGTTA-TAAAGCTGGAGTCAG-3') (dsETS; Gutman and Wasylyk, 1990) was added simultaneously as competitor. The free oligomer, protein-DNA, and antibody-protein-DNA complexes were then separated in a non-denaturing 4% polyacrylamide gel in 0.256TBE (16TBE: 89 mM Tris, 89 mM borate, 2.5 mM disodium EDTA, pH 8.3). The gels were dried and exposed to X-ray ®lm at 7708C.
Western blot analyses
Equal aliquots (10 mg) of nuclear protein from vector and PU.1 transfected stable cell lines were fractionated on SDS ± PAGE (Laemmli, 1970) and transferred to nitrocellulose membrane (Burnette et al., 1981) . The membrane was blocked with 5% (w/v) milk powder/0.1% Tween in PBS overnight, and subsequently incubated for 1 h with the PU.1 antibody mentioned above (5 mg/ml in milk/PBS). Thereafter, the membrane was rinsed once for 15 min and twice for 5 min with 0.1% Tween/PBS, and the bound antibodies were detected using enhanced chemiluminescence detection system (Amersham, UK).
